Pediatrix Medical Group, Inc. (NYSE:MD) Position Boosted by Dana Investment Advisors Inc.

Dana Investment Advisors Inc. lifted its stake in Pediatrix Medical Group, Inc. (NYSE:MD) by 80.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,023,136 shares of the company’s stock after purchasing an additional 455,785 shares during the quarter. Dana Investment Advisors Inc. owned 1.22% of Pediatrix Medical Group worth $7,725,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in MD. The Manufacturers Life Insurance Company raised its stake in shares of Pediatrix Medical Group by 3.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,387 shares of the company’s stock worth $245,000 after purchasing an additional 1,088 shares in the last quarter. ProShare Advisors LLC raised its position in Pediatrix Medical Group by 7.4% during the first quarter. ProShare Advisors LLC now owns 16,937 shares of the company’s stock valued at $170,000 after acquiring an additional 1,167 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in Pediatrix Medical Group by 47.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after acquiring an additional 1,524 shares during the last quarter. SummerHaven Investment Management LLC grew its position in Pediatrix Medical Group by 3.8% in the second quarter. SummerHaven Investment Management LLC now owns 55,951 shares of the company’s stock worth $422,000 after acquiring an additional 2,069 shares in the last quarter. Finally, Bank of Montreal Can increased its stake in shares of Pediatrix Medical Group by 0.5% during the 2nd quarter. Bank of Montreal Can now owns 415,110 shares of the company’s stock worth $3,196,000 after purchasing an additional 2,083 shares during the last quarter. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently issued reports on MD. StockNews.com raised shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research note on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft upgraded Pediatrix Medical Group from a “sell” rating to a “hold” rating and set a $8.00 price target for the company in a research note on Friday, June 7th. UBS Group increased their price objective on Pediatrix Medical Group from $9.00 to $10.50 and gave the company a “neutral” rating in a report on Friday, August 9th. Truist Financial boosted their target price on Pediatrix Medical Group from $8.00 to $10.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Finally, Jefferies Financial Group upgraded Pediatrix Medical Group from a “hold” rating to a “buy” rating and increased their price target for the company from $8.00 to $14.00 in a report on Thursday, September 26th. Five research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.30.

Insider Activity

In related news, CEO James D. Swift sold 11,100 shares of Pediatrix Medical Group stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $10.79, for a total transaction of $119,769.00. Following the sale, the chief executive officer now directly owns 170,001 shares of the company’s stock, valued at $1,834,310.79. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CEO James D. Swift sold 11,100 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the completion of the transaction, the chief executive officer now directly owns 170,001 shares in the company, valued at $1,834,310.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Laura A. Linynsky sold 7,000 shares of Pediatrix Medical Group stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total transaction of $78,120.00. Following the sale, the director now owns 30,805 shares in the company, valued at approximately $343,783.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 68,100 shares of company stock valued at $701,889. Insiders own 2.00% of the company’s stock.

Pediatrix Medical Group Price Performance

NYSE MD opened at $11.60 on Tuesday. The stock has a 50-day simple moving average of $10.12 and a 200 day simple moving average of $8.90. Pediatrix Medical Group, Inc. has a twelve month low of $6.62 and a twelve month high of $13.01. The stock has a market capitalization of $976.11 million, a PE ratio of -13.65, a P/E/G ratio of 1.64 and a beta of 1.56. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.38 and a current ratio of 1.38.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.03. Pediatrix Medical Group had a positive return on equity of 10.59% and a negative net margin of 12.58%. The company had revenue of $504.30 million during the quarter, compared to analysts’ expectations of $505.49 million. During the same period in the prior year, the business earned $0.37 earnings per share. Pediatrix Medical Group’s revenue for the quarter was up .7% compared to the same quarter last year. Research analysts anticipate that Pediatrix Medical Group, Inc. will post 1.19 EPS for the current year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.